Recurrent Tuberculosis Treatment Episodes in Children Presenting With Presumptive Pulmonary Tuberculosis in Cape Town, South Africa.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
12
6
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Limited data are available on tuberculosis (TB) recurrence in children. The aim of this study was to explore the burden of and risk factors for recurrent TB treatment in children. A prospective, observational cohort study of children (0-13 years) presenting with presumptive pulmonary TB in Cape Town, South Africa from March 2012 to March 2017. Recurrent TB was defined as more than 1 episode of TB treatment (microbiologically confirmed and unconfirmed). Of 620 children enrolled with presumptive pulmonary TB, data of 608 children were reviewed for TB recurrence after exclusions. The median age was 16.7 [interquartile range (IQR) 9.5-33.3] months, 324 (53.3%) were male and 72 (11.8%) children living with HIV (CLHIV). TB was diagnosed in 297 of 608 (48.8%), of whom 26 had previously received TB treatment, giving a prevalence of 8.8% recurrence: 22 (84.6%) had 1 and 4 (15.4%) had 2 prior TB treatment episodes. The median age of children with recurrent TB was 47.5 (IQR: 20.8-82.5) months at the current episode: 19 of 26 (73.1%) were CLHIV, of whom 12 of 19 (63.2%) were on antiretroviral therapy for a median 43.1 months and all 12 for longer than 6 months. None of the 9 children on antiretroviral treatment with available viral load (VL) data were virally suppressed (median VL, 22,983 copies/ml). Three of 26 (11.6%) children had documented microbiologically confirmed TB at 2 episodes. Four children (15.4%) received drug-resistant TB treatment at recurrence. There was a high rate of recurrent treatment for TB in this cohort of young children, with CLHIV at the highest risk.
Sections du résumé
BACKGROUND
BACKGROUND
Limited data are available on tuberculosis (TB) recurrence in children. The aim of this study was to explore the burden of and risk factors for recurrent TB treatment in children.
METHODS
METHODS
A prospective, observational cohort study of children (0-13 years) presenting with presumptive pulmonary TB in Cape Town, South Africa from March 2012 to March 2017. Recurrent TB was defined as more than 1 episode of TB treatment (microbiologically confirmed and unconfirmed).
RESULTS
RESULTS
Of 620 children enrolled with presumptive pulmonary TB, data of 608 children were reviewed for TB recurrence after exclusions. The median age was 16.7 [interquartile range (IQR) 9.5-33.3] months, 324 (53.3%) were male and 72 (11.8%) children living with HIV (CLHIV). TB was diagnosed in 297 of 608 (48.8%), of whom 26 had previously received TB treatment, giving a prevalence of 8.8% recurrence: 22 (84.6%) had 1 and 4 (15.4%) had 2 prior TB treatment episodes. The median age of children with recurrent TB was 47.5 (IQR: 20.8-82.5) months at the current episode: 19 of 26 (73.1%) were CLHIV, of whom 12 of 19 (63.2%) were on antiretroviral therapy for a median 43.1 months and all 12 for longer than 6 months. None of the 9 children on antiretroviral treatment with available viral load (VL) data were virally suppressed (median VL, 22,983 copies/ml). Three of 26 (11.6%) children had documented microbiologically confirmed TB at 2 episodes. Four children (15.4%) received drug-resistant TB treatment at recurrence.
CONCLUSIONS
CONCLUSIONS
There was a high rate of recurrent treatment for TB in this cohort of young children, with CLHIV at the highest risk.
Identifiants
pubmed: 37204874
doi: 10.1097/INF.0000000000003922
pii: 00006454-202307000-00004
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-548Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Dodd PJ, Yuen CM, Sismanidis C, et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898–e906.
StopTB Partnership. Tuberculosis situation in 2020 South Africa [Internet]. October 14, 2021. Available at: https://www.stoptb.org/static_pages/ZAF_Dashboard.html . Accessed November 15, 2022.
Lambert ML, Hasker E, Van Deun A, et al. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis. 2003;3:282–287.
Osman M, Welte A, Dunbar R, et al. Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: a pilot study. Int J Infect Dis. 2019;85:57–63.
Comstock GW, Golub JE, Panjabi R. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis. 2007;11:828–837.
Moyo S, Ismail F, Van der Walt M, et al. Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional survey. Lancet Infect Dis. 2022;22:1172–1180.
Marx FM, Hesseling AC, Martinson N, et al. National survey in South Africa reveals high tuberculosis prevalence among previously treated people. Lancet Infect Dis. 2022;22:1273.
Osman M, Lee K, Du Preez K, et al. Excellent treatment outcomes in children treated for tuberculosis under routine operational conditions in Cape Town, South Africa. Clin Infect Dis. 2017;65:1444–1452.
Schaaf HS, Krook S, Hollemans DW, et al. Recurrent culture-confirmed tuberculosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2005;24:685–691.
Middelkoop K, Bekker LG, Shashkina E, et al. Retreatment tuberculosis in a South African community: the role of re-infection, HIV and antiretroviral treatment. Int J Tuberc Lung Dis. 2012;16:1510–1516.
Rosser A, Marx FM, Pareek M. Recurrent tuberculosis in the pre-elimination era. Int J Tuberc Lung Dis. 2018;22:139–150.
Mantshonyane L, Kgwaadira B, Gross R. The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB. Int J Tuberc Lung Dis. 2021;25:511–512.
Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687–1693.
De Boer AS, Borgdorff MW, Vynnycky E, et al. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis. 2003;7:145–152.
Harries AD, Chimzizi RB, Nyirenda TE, et al. Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programmes? Int J Tuberc Lung Dis. 2003;7:616–622.
Wood R, Lawn SD, Caldwell J, et al. Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status. PLoS One. 2011;6:e250981–e250989.
Korenromp EL, Scano F, Williams BG, et al. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003;37:101–112.
Palmer M, Gunasekera KS, van der Zalm MM, et al. The diagnostic accuracy of chest radiographic features for pediatric intrathoracic tuberculosis. Clin Infect Dis. 2022;75:1014–1021.
Walters E. Innovative strategies to improve the diagnosis of intrathoracic tuberculosis in children [dissertation]. Cape Town: Stellenbosch University; 2018:460. Available at: https://scholar.sun.ac.za/handle/10019.1/104844 . Accessed January 11, 2022.
Allwood BW, Koegelenberg CFN, Irusen E, et al. Clinical evolution, management and outcomes of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: a research protocol. BMJ Open. 2020;10:1–6.
Walters E, van der Zalm MM, Palmer M, et al. Xpert MTB/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease. Pediatr Infect Dis J. 2017;36:837–843.
Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. Clin Infect Dis. 2015;61(Suppl 3):S179–S187.
Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55:32–38.
Byamungu LN, du Preez K, Walters E, et al. Timing of HIV diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa. Int J Tuberc Lung Dis. 2018;22:488–495.
Dodd PJ, Prendergast AJ, Beecroft C, et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017;72:559–575.
South African National Department of Health. Guidelines for the Management of Tuberculosis in Children. Department of Health, Republic of South Africa; 2013:57.
Nkereuwem E, Agbla S, Sallahdeen A, et al. Reduced lung function and health-related quality of life after treatment for pulmonary tuberculosis in Gambian children: a cross-sectional comparative study. Thorax. 2023;78:281–287.
Concepcion NDP, Laya BF, Andronikou S, et al. Standardized radiographic interpretation of thoracic tuberculosis in children. Pediatr Radiol. 2017;47:1237–1248.